Literature DB >> 20921943

Delayed platelet recovery after allogeneic transplantation: a predictor of increased treatment-related mortality and poorer survival.

P Ramírez1, C G Brunstein, B Miller, T Defor, D Weisdorf.   

Abstract

Delayed platelet recovery (DPR) is common after allo-SCT. Insufficient data on risk factors and association with OS and TRM are available. We conducted a retrospective analysis of all allografts at the University of Minnesota between 2000 and 2005 to characterize the frequency of DPR (platelets <50 000/μL by day 60), risk factors and related complications. A total of 850 patients with hematological malignancies and benign disorders were included. Myeloablative (MA) conditioning was used in 65% of the patients and 45% received umbilical cord blood (UCB) grafts. The 60-day cumulative incidence of platelet recovery was 40% in UCB, 57% in unrelated donor (URD) and 74% in sibling donor. Multivariate analysis confirmed that the variables associated with DPR were MA (versus reduced intensity) conditioning, graft source other than sibling donor, ABO major mismatch, recipient CMV-positive serostatus, the presence of grade II-IV acute GVHD and slower neutrophil recovery. These data demonstrate that DPR is frequent after allogeneic hematopoietic cell transplantation, especially after UCB. DPR is a significant independent risk factor for increased TRM and poorer OS along with HLA-mismatched URD, but not UCB, grade II-IV acute GVHD, old age and advanced disease stage.

Entities:  

Mesh:

Year:  2010        PMID: 20921943     DOI: 10.1038/bmt.2010.218

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  21 in total

1.  Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival.

Authors:  Koen van Besien; Parameswaran Hari; Mei-Jie Zhang; Hong-Tao Liu; Wendy Stock; Lucy Godley; Olatoyosi Odenike; Richard Larson; Michael Bishop; Amittha Wickrema; Usama Gergis; Sebastian Mayer; Tsiporah Shore; Stephanie Tsai; Joanna Rhodes; Melissa M Cushing; Sandra Korman; Andrew Artz
Journal:  Haematologica       Date:  2016-02-11       Impact factor: 9.941

Review 2.  Alternative donor transplantation--"mixing and matching": the role of combined cord blood and haplo-identical donor transplantation (haplo-cord SCT) as a treatment strategy for patients lacking standard donors?

Authors:  Hongtao Liu; Koen van Besien
Journal:  Curr Hematol Malig Rep       Date:  2015-03       Impact factor: 3.952

3.  Combination of a haploidentical SCT with an unrelated cord blood unit: a single-arm prospective study.

Authors:  J Chen; R-X Wang; F Chen; A-N Sun; H-Y Qiu; Z-M Jin; X-W Tang; Y Han; Z-Z Fu; G-S He; M Miao; X Ma; D-P Wu
Journal:  Bone Marrow Transplant       Date:  2013-10-21       Impact factor: 5.483

4.  Myeloablative conditioning regimens with combined of haploidentical and cord blood transplantation for myelodysplastic syndrome patients.

Authors:  P Ke; X-B Bao; X-H Hu; J Zhuang; X-J Wu; Y-J Liu; X-F He; D-P Wu; S-L Xue; X Ma
Journal:  Bone Marrow Transplant       Date:  2017-10-30       Impact factor: 5.483

5.  A phase I/II trial of intrabone marrow cord blood transplantation and comparison of the hematological recovery with the Japanese nationwide database.

Authors:  N Kurita; M Gosho; Y Yokoyama; T Kato; N Obara; M Sakata-Yanagimoto; Y Hasegawa; N Uchida; S Takahashi; Y Kouzai; Y Atsuta; M Kurata; T Ichinohe; S Chiba
Journal:  Bone Marrow Transplant       Date:  2017-01-09       Impact factor: 5.483

Review 6.  Acute graft-versus-host disease: a bench-to-bedside update.

Authors:  Shernan G Holtan; Marcelo Pasquini; Daniel J Weisdorf
Journal:  Blood       Date:  2014-06-09       Impact factor: 22.113

7.  The impact of CD34+ cell dose on engraftment after SCTs: personalized estimates based on mathematical modeling.

Authors:  T Stiehl; A D Ho; A Marciniak-Czochra
Journal:  Bone Marrow Transplant       Date:  2013-09-23       Impact factor: 5.483

Review 8.  Umbilical cord blood transplantation supported by third-party donor cells: rationale, results, and applications.

Authors:  Koen Van Besien; Hongtao Liu; Nitin Jain; Wendy Stock; Andrew Artz
Journal:  Biol Blood Marrow Transplant       Date:  2012-11-08       Impact factor: 5.742

9.  Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions.

Authors:  Hongtao Liu; Elizabeth S Rich; Lucy Godley; Olatoyosi Odenike; Loren Joseph; Susana Marino; Justin Kline; Vu Nguyen; John Cunningham; Richard A Larson; Paula del Cerro; Linda Schroeder; Lisa Pape; Wendy Stock; Amittha Wickrema; Andrew S Artz; Koen van Besien
Journal:  Blood       Date:  2011-10-05       Impact factor: 22.113

10.  Double umbilical cord blood transplantation in patients with hematologic malignancies using a reduced-intensity preparative regimen without antithymocyte globulin.

Authors:  F Ostronoff; F Milano; T Gooley; J A Gutman; P McSweeney; F B Petersen; B M Sandmaier; R Storb; C Delaney
Journal:  Bone Marrow Transplant       Date:  2012-12-17       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.